NCT04947423View on ClinicalTrials.gov

Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion

PHASE3CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

June 14, 2021

Primary Completion Date

August 12, 2021

Study Completion Date

August 12, 2021

Conditions
Motion Sickness
Interventions
DRUG

DPI-386 Nasal Gel

Subjects will self-administer DPI-386 Nasal Gel or Placebo

DRUG

Placebo

Subjects will self-administer DPI-386 Nasal Gel or Placebo

Trial Locations (1)

90404

Santa Monica Clinical Trials, Santa Monica

Sponsors
All Listed Sponsors
collaborator

Defender Pharmaceuticals, Inc.

INDUSTRY

lead

Repurposed Therapeutics, Inc.

INDUSTRY